Skip to search formSkip to main contentSkip to account menu

NVA237

Known as: 237, NVA, NVA 237, NVA-237 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Glycopyrrolate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
BACKGROUND Three classes of inhaler medications are used to manage chronic obstructive pulmonary disease (COPD): long-acting beta… 
Highly Cited
2012
Highly Cited
2012
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
Introduction Exercise limitation, dynamic hyperinflation, and exertional dyspnea are key features of symptomatic chronic… 
Review
2012
Review
2012
Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
Background: Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive… 
2012
2012
Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD).
OBJECTIVE NVA237 (glycopyrronium bromide) is a once-daily longacting muscarinic antagonist (LAMA) in development for the… 
Review
2011
Review
2011
NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease
Bronchodilation with a long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist is central to the management of chronic… 
Review
2010
Review
2010
Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease
Importance of the field: The prevention and relief of symptoms by regular use of bronchodilators is central to the… 
Highly Cited
2010
Highly Cited
2010
Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol
Abstract Objective: To report performance characteristics and robustness of the Breezhaler device, a new capsule based dry powder… 
Highly Cited
2010
Highly Cited
2010
Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Highly Cited
2010
Highly Cited
2010
Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Review
2008
Review
2008
Novel long‐acting bronchodilators for COPD and asthma
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)